Aspirin may reduce death in hospitalized COVID-19 patients
Researchers at George Washington University presented the results of the world’s biggest cohort study, which found that hospitalised patients with moderate COVID-19 who were given aspirin early in their therapy had a decreased risk of dying than patients who were not given aspirin.
Jonathan Chow, the lead researcher, stated, “This is our third trial and the culmination of 15 months of research into aspirin use in COVID-19 hospitalised patients. Aspirin use continues to be related with better outcomes and decreased rates of death in hospitalised patients. Furthermore, it is inexpensive and widely available, which is significant in places of the world where more expensive treatments may be unavailable.”
The largest data set included in the study included 112,269 patients hospitalised with mild COVID-19. Patients registered from January 1, 2020, to September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health’s National COVID Cohort Collaborative were included in the study (N3C).
When aspirin was given on the first day of admission to patients with intermediate illness severity, researchers discovered a 1.6 percent reduction in mortality and that patients were less likely to form blood clots. They also discovered that elderly individuals and those with one or more comorbidities benefit the most from early aspirin therapy.
Read Also :DOCTORS’ STRIKE IS STILL GOING ON, PARALYSING MEDICAL SERVICES
Contact us : FacebookÂ
